Iñigo Azcoitia

Iñigo Azcoitia

Auto-generated profile, based on publicly available information

Iñigo Azcoitia

Departamento de Biología Celular, Facultad de Biología, Universidad Complutense de Madrid, E-28040 Madrid, Spain

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2001 in Progress in Neurobiology
Verified
Journal Article
Closed access
LGLuis Miguel Garcia-Segura
Luis Miguel Garcia-Segura
IAIñigo Azcoitia
Iñigo Azcoitia
LDLydia L. DonCarlos
Lydia L. DonCarlos

26 November 2014 in Nature Reviews Neuroscience
Verified
Journal Article
Closed access
M.-A. ArevaloM.-A. Arevalo
M.-A. Arevalo
IAIñigo Azcoitia
Iñigo Azcoitia
LGLuis Miguel Garcia-Segura
Luis Miguel Garcia-Segura

5 October 2009 in Brain
Verified
Journal Article
Open access
PDF file
JPJavier Palazuelos
Javier Palazuelos
TATania Aguado
Tania Aguado
MPM. Ruth Pazos
M. Ruth Pazos
BJBoris Julien
Boris Julien
CCCarolina Carrasco
Carolina Carrasco
IGIsmael Galve-Roperh
Ismael Galve-Roperh
Cannabinoid-derived drugs are promising agents for the development of novel neuroprotective strategies. Activation of neuronal CB1 cannabinoid receptors attenuates excitotoxic glutamatergic neurotransmission, triggers prosurvival signalling pathways and palliates motor symptoms in animal models of neurodegenerative disorders. However, in Huntington's disease there is a very early downregulation of CB1 receptors in striatal neurons that, together with the undesirable psychoactive effects triggered by CB1 receptor activation, foster the search for alternative pharmacological treatments. Here, we show that CB2 cannabinoid receptor expression increases in striatal microglia of Huntington's disease transgenic mouse models and patients. Genetic ablation of CB2 receptors in R6/2 mice, that express human mutant huntingtin exon 1, enhanced microglial activation, aggravated disease symptomatology and reduced mice lifespan. Likewise, induction of striatal excitotoxicity in CB2 receptor-deficient mice by quinolinic acid administration exacerbated brain oedema, microglial activation, proinflammatory-mediator state and medium-sized spiny neuron degeneration. Moreover, administration of CB2 receptor-selective agonists to wild-type mice subjected to excitotoxicity reduced neuroinflammation, brain oedema, striatal neuronal loss and motor symptoms. Studies on ganciclovir-induced depletion of astroglial proliferation in transgenic mice expressing thymidine kinase under the control of the glial fibrillary acidic protein promoter excluded the participation of proliferating astroglia in CB2 receptor-mediated actions. These findings support a pivotal role for CB2 receptors in attenuating microglial activation and preventing neurodegeneration that may pave the way to new therapeutic strategies for neuroprotection in Huntington's disease as well as in other neurodegenerative disorders with a significant excitotoxic component.

1 March 1999 in Neuroscience
Verified
Journal Article
Closed access
LGLuis Miguel Garcia-Segura
Luis Miguel Garcia-Segura
AWA. Wozniak
A. Wozniak
IAI. Azcoitia
I. Azcoitia
JRJ.R. Rodriguez
J.R. Rodriguez
RHR.E. Hutchison
R.E. Hutchison
JHJ.B. Hutchison
J.B. Hutchison

21 May 2001 in Journal of Neurobiology
Verified
Journal Article
Closed access
PDF file
IAIñigo Azcoitia
Iñigo Azcoitia
ASAmanda Sierra
Amanda Sierra
SVSergio Veiga
Sergio Veiga
SHShin‐Ichiro Honda
Shin‐Ichiro Honda
NHNobuhiro Harada
Nobuhiro Harada
LGLuis Miguel Garcia-Segura
Luis Miguel Garcia-Segura

1 September 2011 in Neuroscience
Verified
Journal Article
Closed access
IAI. Azcoitia
I. Azcoitia
JYJ.G. Yague
J.G. Yague
LGLuis Miguel Garcia-Segura
Luis Miguel Garcia-Segura